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Abstract: Liver transplant is the unique curative therapy for patients with acute liver failure or
end-stage liver disease, with or without hepatocellular carcinoma. Increase of body weight, onset
of insulin resistance and drug-induced alterations of metabolism are reported in liver transplant
recipients. In this context, post-transplant diabetes mellitus, hyperlipidemia, and arterial hypertension
can be often diagnosed. Multifactorial illnesses occurring in the post-transplant period represent
significant causes of morbidity and mortality. This is especially true for metabolic syndrome.
Non-alcoholic steatosis and steatohepatitis are hepatic manifestations of metabolic syndrome and after
liver transplant both recurrent and de novo steatosis can be found. Usually, post-transplant steatosis
shows an indolent outcome with few cases of fibrosis progression. However, in the post-transplant
setting, both metabolic syndrome and steatosis might play a key role in the stratification of morbidity
and mortality risk, being commonly associated with cardiovascular disease. The single components
of metabolic syndrome can be treated with targeted drugs while lifestyle intervention is the only
reasonable therapeutic approach for transplant patients with non-alcoholic steatosis or steatohepatitis.
Keywords: liver transplant; multifactorial disease; metabolic syndrome; non-alcoholic fatty liver
disease; non-alcoholic steatohepatitis
1. Introduction
Liver transplant (LT) represents the curative treatment for patients with acute liver failure,
end-stage liver disease and/or non-resectable hepatocellular carcinoma worldwide. After surgery,
transplanted patients often develop an increase of body weight, insulin resistance (IR) and metabolic
alterations [1]. Multifactorial disease such as diabetes mellitus (DM), hyperlipidemia and arterial
hypertension are common complications after LT, all negatively affecting quality of life, morbidity
and mortality [1]. Consolidated immunosuppressant drugs such as corticosteroids, calcineurin
inhibitors (CNIs) (cyclosporine (CSA) and tacrolimus (TAC)) and mammalian target of rapamycin
inhibitors (mTORs) (such as sirolimus (SIR)) play a key role in the metabolic balance, favoring
hyperglycemia, arterial hypertension and hyperlipidemia [2]. In this context, a significant amount of
transplanted patients fulfill the criteria of metabolic syndrome (MS) which is strongly associated with
an increased cardiovascular risk [1]. Since non-alcoholic fatty liver disease (NAFLD) and non-alcoholic
steatohepatitis (NASH) are considered the liver expression of MS, it is not surprising that both recurrent
and de novo NAFLD/NASH can be found after LT [3]. Although post-LT steatosis shows an indolent
outcome in terms of fibrosis progression, NAFLD/NASH should be considered for the stratification
of morbidity and mortality risk of transplant patients. Notably, cardiovascular disease represents
the major cause of death unrelated to liver disease and the third most common cause of mortality
among transplant patients, accounting for 12%–16% of deaths. Today, targeted drugs for MS and
NAFLD/NASH do not exist. Clinicians can use specific drugs against the single components of MS
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while a strong improvement of behavior in terms of diet and aerobic exercise is the only reasonable
approach for recurrent or de novo NAFLD/NASH [1].
This review article focuses on the current literature regarding the main metabolic diseases affecting
transplanted patients, the clinical impact of post-LT MS and NAFLD/NASH and, finally, the feasible
therapeutic strategies.
2. Multifactorial Disease after Liver Transplant
The majority of transplant patients develop a rise in body weight after surgery. The highest
weight increase occurs after the first six months and at one and three years from LT, and the median
weight gain is 5.1 and 9.5 kg, respectively. Notably, at one and three years, 24% and 31% of transplant
patients become obese [4]. However, the above-cited authors [4] reported that the vast part of enrolled
patients were also obese before LT. Considering only patients who were not obese at the time of surgery,
15.5% at one year and 26.3% at three years had a body mass index (BMI) >30 [4]. In a further study,
23 patients were followed for nine months after LT. At the end of the study, 87 of the subjects were
overweight or obese with a significant increase in fat mass and a minor improvement in lean mass [5].
Another study [6] showed progressive weight gain in the first year after LT, with one-third of patients
becoming obese at the end of observation. Considering a follow-up of four years, overweight and
obesity were found in 58% and 21% of cases and high BMI before LT was the main risk factor of post-LT
obesity [7].
In this context, DM, hyperlipidemia and arterial hypertension can be often diagnosed after LT [1]
(see Table 1).
Table 1. Multifactorial conditions affecting transplant patients.
Disease Incidence Risk Factors References
Diabetes mellitus 10%–64%
Male gender, high pre-LT BMI, family history, hepatitis
C, older age, immunosuppressants, rapamycin gene
polymorphisms, TCF7L2 gene polymorphisms (donor)
[8–11]
Hyperlipidemia 45%–69%
Diet, older age, high BMI, DM, renal impairment,
immunosuppressants, low-density lipoprotein
receptor gene polymorphism (donor)
[12–15]
Arterial hypertension 50%–100% Obesity, older age, impaired glycemia,immunosuppressants [9,16,17]
LT: liver transplant; BMI, body mass index; TCF7L2, Transcription factor 7-like 2; DM, diabetes mellitus.
Post-LT DM is associated with more significant morbidity with respect to pre-LT disease,
determining an increased risk of post-operative infection and cardiovascular events [8,18].
The incidence of post-LT DM ranges from 10% to 64% [9]. Ahn et al. [19] showed that among
74 patients transplanted with post-LT DM, post-LT DM was transient in 56.8%, while in the others
it was persistent. Although the underlying mechanisms are not yet clear, the main risk factors for
the onset of post-LT DM are the following: male gender, high pre-LT BMI, positive family history,
hepatitis C virus infection, older age, high dosage of immunosuppressant drugs and rapamycin gene
polymorphisms [8]. A meta-analysis confirmed that male gender, high pre-LT BMI and positive family
history are predictive of post-LT DM development [10]. Transcription factor 7-like 2 (TCF7L2) protein
regulates cell proliferation and differentiation modifying the insulin secretion [20]. Notably, it was
reported that polymorphisms of the TCF7L2 gene in LT donors are another independent risk factor of
post-LT DM [11].
Among transplanted patients, a percentage ranging from 45% to 69% develops hyperlipidemia,
which is a significant risk factor for cardiovascular morbidity and mortality [12]. Increased nutrient
intake, older age, body weight, presence of DM, renal impairment, immunosuppressive drugs, such as
steroids, CSA, TAC, and SIR, are risk factors for post-LT hyperlipidemia [13,14]. Interestingly,
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the polymorphism of the low-density lipoprotein receptor gene in the donor may facilitate the
development of hyperlipidemia in the recipient [15].
Arterial hypertension, an uncommon feature in subjects with chronic liver disease, arises in
50%–100% of patients after LT [9,16]. Post-LT hypertension usually develops in the first six months
after LT as a consequence of systemic vasoconstriction, elevation in plasma endothelin-1 concentrations,
and increased arterial stiffness [21]. Occurrence of post-LT hypertension is favored by obesity and
older age and is often associated with impaired glycemia. Moreover, it is well known that both CNIs
and corticosteroids have negative effects on pressure control [17].
3. Metabolic Impact of Immunosuppressant Drugs
It is well known that immunosuppressive agents might exert negative metabolic effects [22] (see
Table 2).
Table 2. Most used immunosuppressant drugs and main metabolic side effects.
Drug Side Effects References
Corticosteroids
Increased fat depositions, decreased fat oxidation, increased
proteolysis, reduced protein synthesis, IR, hyperlipidemia, sodium
retention, NAFLD
[23–25]
CSA Decreased energy metabolism and muscle mass, weight gain,hyperlipidemia, arterial hypertension [26–30]
TAC DM, hyperlipidemia, arterial hypertension [10,27–30]
SIR Decreased muscle mass, hyperlipidemia, glycemic alteration [31–33]
CSA: cyclosporine; TAC: tacrolimus; SIR: sirolimus; IR, insulin resistance; NAFLD, non-alcoholic fatty liver
disease; DM, diabetes mellitus.
Corticosteroids represent a key component of the immunosuppressant protocol in the first months
after LT but are also necessary in the long-term management of patients transplanted for autoimmune
or cholestatic liver disease. Corticosteroids show dose-related metabolic side effects. They increase
appetite and fat depositions, drop fat oxidation, and lead to increased proteolysis and reduced
protein synthesis [23,24]. Moreover, high doses of corticosteroids determine the rise of both IR and
gluconeogenesis [25]. Corticosteroids also negatively alter lipid metabolism and steroid-free protocols
might lead to a significant decrease in hypertriglyceridemia [34]. Corticosteroids also influence
mineralocorticoid metabolism, causing sodium retention. Interestingly, steroids directly correlate with
NAFLD/NASH occurrence in liver allografts [35].
CNIs may negatively affect energy metabolism and muscle mass [26] and CSA represents
an independent predictor of post-LT weight gain [36]. Through a meta-analysis including 10 studies,
Li et al. [10] demonstrated that TAC is an independent risk factor for post-LT DM. Regarding lipid
metabolism, CSA has a more negative effect in comparison with TAC. The incidence of hyperlipidemia
is higher in patients treated with CSA than with TAC (14% versus 5% and 49% versus 17%) [27,28].
CNIs also favor the onset of arterial hypertension determining arterial vasoconstriction. Among
CNIs, TAC seems to have a lesser impact on arterial pressure in comparison to CSA, but data are not
conclusive [29,30]. As expected, minimizing the use of CNIs improves their metabolic profile and,
consequently, the long-term outcome of patients [37,38].
SIR increases triglyceride production, being the most dangerous immunosuppressant in terms
of lipid alteration. Among patients treated with SIR, 55% develop hyperlipidemia [31]. In addition,
SIR alters the insulin signaling pathway [31] and negatively affects muscle mass status [32]. Recently,
Zimmermann et al. [33] conducted a study involving 92 transplant patients, reporting that patients
treated with mTORs were at higher risk of hyperlipidemia and glycemic alteration with respect to
patients under CNIs.
Int. J. Mol. Sci. 2016, 17, 490 4 of 11
4. Metabolic Syndrome after Transplant
The definition of MS includes a combination of at least three of the following factors: arterial
hypertension, IR, hypertriglyceridemia, low high-density lipoprotein and obesity [39]. In the post-LT
period, MS can be found in 50%–60% of patients. MS represents a relevant risk factor for atherosclerosis
and cardiovascular disease, which are the main causes of post-LT morbidity and mortality [39].
Interestingly, the prevalence of post-LT MS is about twice that of the general North American
population [40]. Older age, obesity, pre-LT DM, genetic polymorphisms in the living donor and
the use of high-dosage immunosuppressive drugs are risk factors for post-LT MS [9]. Sprinzl et al. [41]
analyzed a cohort of 170 transplant patients with a follow-up of two years. The authors showed
that de novo MS was present in one-third of patients and glycosylated hemoglobin ě5% and arterial
hypertension were independent risk factors for it. Moreover, the authors demonstrated a negative
dose-dependent role for steroids. It was also confirmed that in the post-LT period, MS could be
considered as a link toward NAFLD/NASH. Interestingly, it was reported that changes in intestinal
microbiota might also play a relevant role in the development of MS after LT [42]. Fussner et al. [43]
retrospectively analyzed 455 consecutive LT recipients with a long follow-up (8–12 years), suggesting
that increased BMI was a strong predictor of MS at one year from the LT. Consequently, the authors
suggested that preventing weight gain in the early months after LT might decrease the probability of
MS. However, the authors suggested that older age, post-LT DM, prior family history of cardiovascular
disease, altered serum troponin, but not MS, were independent predictors of cardiovascular events.
It has to be underlined that specific treatments for MS are not yet available, while the only feasible
way to manage it is to treat its single components [44].
5. Post-Transplant Non-Alcoholic Fatty Liver Disease
In the pre-LT period, NAFLD and NASH represent the liver expression of altered metabolic status
being associated in a large number of cases to IR, dyslipidemia and obesity. Considering the significant
prevalence of metabolic diseases after LT, it is clear why both recurrent and de novo NAFLD/NASH
can be found in transplant patients [41].
Burra et al. [45] reported that NASH recurrence ranges from 20% to 40%, this wide variability
depending on the methodology used for the diagnosis. Notably, in the majority of cases the outcome
of recurrent NAFLD/NASH is harmless, without an evolution toward cirrhosis [46]. Nevertheless,
patients with recurrent NAFLD/NASH more frequently show cardiovascular disease and worse
infection-related morbidity and mortality. This is evident considering that the recurrence of NASH
is associated with DM, weight gain, and dyslipidemia [47]. Interestingly, genetic predisposition
might play a role in the recurrence of NAFLD and NASH. The presence of the rs738409-G allele of
the Patatin-like phospholipase in the LT recipients represents an independent risk factor for post-LT
obesity, DM and steatosis [48,49].
The leading risk factors for the development of de novo NAFLD/NASH are the following: obesity,
hyperlipidemia, DM, arterial hypertension, TAC-based immunosuppression, pre-LT alcoholic cirrhosis
and liver graft steatosis [50]. Sprinzl et al. [41] analyzed the association between MS and post-LT
NAFLD/NASH. Mixed vesicular steatosis was observed in 34.1% of patients. Hepatic steatosis was
mild, moderate, and severe in 16.5%, 7.1%, and 2.9% of cases. Among patients with MS and steatosis,
NASH was diagnosed only in 5.4% of patients, confirming that post-LT metabolic liver disease might
be relevant not as a primary liver disease but as an indicator of cardiovascular risk. Remarkably,
NAFLD/NASH patients showed higher triglyceride levels, elevated uric acid and higher BMI with
respect to patients with MS but without liver disease. The authors demonstrated that obesity and
dyslipidemia but not arterial hypertension and DM favored the onset of NAFLD/NASH among
transplanted patients with MS. Another interesting assumption was that a BMI greater than 28.9 was
the only specific risk factor for histological NASH. Mikolasevic et al. [51] identified the association
between NAFLD/NASH and the development of post-LT cardiovascular and chronic kidney disease.
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Consequently, according to these authors, diagnosing NAFLD/NASH in the post-LT period might
improve the stratification of cardiovascular and kidney damage risk.
6. Therapeutic Approach against Post-Transplant Dysmetabolism
The knowledge of pathogenesis is central for understanding the rationale of the therapeutic
approach against MS and NAFLD/NASH. The onset of IR represents a true turning point. In fact,
IR determines a status of chronic inflammation that favors the other metabolic alterations [52].
The molecular basis of IR depends on both genetic and non-genetic mechanisms. IR determines a chain
of events involving inflammation, hypercoagulability, and atherogenesis. Notably, IR occurs firstly
in the vascular structures, and this is one of the main reasons for its association with cardiovascular
disease [53]. Regarding the NAFLD/NASH, the latest proposed model is the “multiparallel hits” [54].
According to this hypothesis, many events happen in parallel, and all are potential therapeutic targets.
The main pathological characters are IR, oxidative stress, adipose and pancreatic tissues, altered lipid
metabolism, bile acids, gut microbiota, and bacterial endotoxins.
As we reported, transplant patients often develop IR and an increase in body weight [1].
Interestingly, Kouz et al. [55] demonstrated that in patients transplanted for NASH-cirrhosis, most of
the weight gain occurs in the first year after LT, while the increase of the weight is more progressive
in subjects with a different etiology. However, regardless of the kind of pre-LT liver disease, after
LT a relevant increase in dietary intake can be found, especially in patients with pre-LT severe
dietary restrictions, gastrointestinal symptoms or anorexia. In detail, from the pre-LT period to one
year after LT, calories rise from 27 to 32 kCal/kg and proteins from 0.8 to 1.3 g/kg per day [56].
Richardson et al. [5] showed that in overweight or obese transplant patients, more significant energy
intake, higher consumption of both proteins and carbohydrates and doubled intake of fat can be found
with respect to the pre-LT period.
The feasible pharmacological tools for treating the single metabolic disease, associated or not with
NAFLD/NASH, should be used with caution for the possible drug-drug interactions [57]. Notably,
a single drug for post-LT MS is not available. Based on these considerations, the main intervention
after surgery should be a strong lifestyle control for both prevention and treatment of MS. However,
the only randomized trial of exercise and dietary counseling after LT published in 2006 did not show a
real advantage with this approach [58]. In this study, 151 liver transplant patients, randomized into
exercise and dietary counseling or usual care, showed a similar increase in body weight, fat mass and
lean mass. It should be underlined that full adherence to exercise and nutrition was obtained only in
37% of subjects.
Many drugs have been proposed for the treatment of NAFLD/NASH, but lifestyle intervention
should be the first-line therapy. In particular, lifestyle modification is the standard of care according
to the Italian, European, Asian-Pacific and North American guidelines [59–62]. The main targets for
the usefulness evaluation should be a weight loss of 7% and 150 min/week of physical activity [63,64].
In particular, a weight loss of 7% has been seen to significantly decrease fat accumulation and
reduce necroinflammation in non-transplanted patients with NAFLD/NASH [63]. Markedly, aerobic
and resistance physical activity have an independent positive effect in decreasing fat in the liver,
regardless of the weight loss [65,66]. Furthermore, clinicians should take into account that the physical
activity per se improves cardio-respiratory fitness [67,68]. Vitamin E and pioglitazone represent the
first-line pharmacological options. Both vitamin E and pioglitazone improve fat accumulation and
liver inflammation. However, the use of vitamin E is limited to patients without DM and it has
no clear effects on fibrosis. On the other hand, pioglitazone shows a negative impact on patients’
weight. In addition, the long-term safety of these drugs is uncertain. Many other drugs such as
metformin, ursodeoxycholic acid, statins, pentoxifylline, and orlistat have been tested in pilot studies
or randomized clinical trials with few results in terms of efficacy. Telmisartan, a safe antihypertensive
drug, is an emerging drug with an interesting preliminary effect on NAFLD/NASH. It seems to have a
positive impact on IR, liver steatosis, inflammation, and fibrosis [52]. As recently reported in a review
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article by Lassailly et al. [69], many other drugs are in progress for the treatment of NAFLD/NASH,
including obeticholic acid, liraglutide and elafibranor. Authors also suggest that bariatric surgery may
be successful in well-selected obese patients with NAFLD/NASH.
Concerning the transplanted patient, none of the cited therapeutic options have been validated.
7. Conclusions
Starting in the first months after surgery, transplant patients tend to develop overweight or
obesity, IR and, consequently, multifactorial diseases. Consequently, a high prevalence of multifactorial
disease such as DM, hyperlipidemia and arterial hypertension can be found. All these metabolic
features negatively influence the outcome of transplant patients in terms of quality of life, morbidity
and mortality.
All the main immunosuppressant drugs, such as corticosteroids, CSA, TAC and SIR, favor the
onset of metabolic alterations. Corticosteroids are surely very important in the first months after LT
but also in the long-term in selected cases. They lead to weight gain and fat accumulation negatively
affecting lipid, glycemic and pressure profiles. Moreover, they directly increase the risk of steatosis
development. CNIs have a negative metabolic impact since they increase weight gain and reduce
muscle mass. TAC seems to be superior compared to CSA concerning the metabolic risk in terms
of the alteration of lipid and arterial pressure. It should be the first choice among CNIs. SIR is the
immunosuppressant with the worst lipid profile. Moreover, SIR shows a worse glycemic profile with
respect to CNIs and has a negative effect on the muscle mass status. The choice of immunosuppressant
is central and related to many aspects and evaluations such as the cardiovascular and renal risks.
In general, one of the main aims of clinicians should be to minimize the dosage of immunosuppressants.
This last assumption is true especially in the long-term period and in patients with pre-LT etiology
different from autoimmune or cholestatic disease and without a history of graft rejection.
The presence of criteria for MS is frequent in the post-LT period and represents the main indicator
of cardiovascular-related morbidity and mortality. NAFLD and its progressive form, represented by
NASH, can be considered the liver expression of MS. Indeed, both recurrent and de novo NAFLD can be
diagnosed in transplanted patients. The hepatic outcome of steatosis after surgery is generally not very
aggressive, with few percentages of advanced fibrosis, in comparison with the pre-LT phase. However,
together with MS, steatosis is a relevant indicator of increased cardiovascular risk. This assumption is
important if we consider that cardiovascular disease is found in 10.6%, 20.7%, and 30.3% of recipients
at one, five, and eight years from the LT [43]. Interestingly, post-LT NAFLD/NASH is also associated
with an increased risk of infections and renal injury.
Clinicians might definitely use the diagnosis of NAFLD in the post-LT period as an indicator
of increased cardiovascular and renal risk. Transplant patients with a first diagnosis of NAFLD
should be closely monitored regarding peripheral atherosclerotic signs and kidney function. In this
direction, the development of diagnostic algorithms with the use non-invasive tools is warranted.
Karlas et al. [70] demonstrated that modern non-invasive liver graft assessments such as hepatic
ultrasound and transient elastography might be able to properly detect both steatosis and graft fibrosis.
Specific therapeutic options against post-LT MS or NAFLD are not available. Targeted
pharmacological tools can be used for each component of MS. So far, a strong behavioral change
in terms of diet and aerobic exercise is the only reasonable approach for transplant patients for both
primary and secondary care. Transplant patients should be educated starting from the first weeks
after surgery for preventing the development of multifactorial diseases, MS and metabolic liver illness.
A well-done stratification of the cardiovascular risk should be developed as soon as possible after
LT. In the next years, the genetic study of recipients and donors might improve the quality of organ
allocation, decreasing the metabolic complications after LT.
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